Cumberland Partners Ltd Cuts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cumberland Partners Ltd decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 29.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,768 shares of the medical research company's stock after selling 14,600 shares during the quarter. Thermo Fisher Scientific comprises approximately 1.5% of Cumberland Partners Ltd's investment portfolio, making the stock its 22nd largest position. Cumberland Partners Ltd's holdings in Thermo Fisher Scientific were worth $21,506,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Beaumont Financial Advisors LLC grew its stake in Thermo Fisher Scientific by 0.8% during the 1st quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company's stock valued at $1,278,000 after purchasing an additional 17 shares during the last quarter. Cedar Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 14.5% in the first quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company's stock worth $78,000 after purchasing an additional 17 shares during the period. Lafayette Investments Inc. boosted its position in Thermo Fisher Scientific by 2.1% during the second quarter. Lafayette Investments Inc. now owns 830 shares of the medical research company's stock worth $459,000 after purchasing an additional 17 shares during the period. IFG Advisors LLC raised its stake in Thermo Fisher Scientific by 3.3% during the third quarter. IFG Advisors LLC now owns 532 shares of the medical research company's stock worth $329,000 after acquiring an additional 17 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. lifted its holdings in shares of Thermo Fisher Scientific by 1.8% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company's stock valued at $570,000 after purchasing an additional 18 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 9,000 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the sale, the chief executive officer now directly owns 14,608 shares of the company's stock, valued at approximately $8,076,178.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the sale, the chief executive officer now owns 14,608 shares in the company, valued at approximately $8,076,178.88. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,150 shares of company stock worth $20,651,865 in the last three months. Insiders own 0.34% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Bank of America upped their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Royal Bank of Canada dropped their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. UBS Group upgraded Thermo Fisher Scientific to a "strong-buy" rating in a research report on Monday, September 16th. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an "overweight" rating in a report on Friday, September 20th. Finally, Barclays dropped their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research note on Wednesday, October 23rd. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $649.33.

Thermo Fisher Scientific Stock Down 1.2 %

Shares of Thermo Fisher Scientific stock traded down $6.29 during trading on Tuesday, reaching $540.63. The stock had a trading volume of 1,723,815 shares, compared to its average volume of 1,462,758. Thermo Fisher Scientific Inc. has a 52 week low of $439.11 and a 52 week high of $627.88. The stock has a fifty day moving average price of $592.59 and a two-hundred day moving average price of $583.56. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $206.79 billion, a price-to-earnings ratio of 34.29, a P/E/G ratio of 3.65 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the previous year, the company posted $5.69 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.